IE45208B1 - Neutralizing agent - Google Patents
Neutralizing agentInfo
- Publication number
- IE45208B1 IE45208B1 IE1120/77A IE112077A IE45208B1 IE 45208 B1 IE45208 B1 IE 45208B1 IE 1120/77 A IE1120/77 A IE 1120/77A IE 112077 A IE112077 A IE 112077A IE 45208 B1 IE45208 B1 IE 45208B1
- Authority
- IE
- Ireland
- Prior art keywords
- acid
- polyethyleneimine
- aqueous solution
- agent according
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Control Of Combustion (AREA)
- Manufacturing Of Printed Circuit Boards (AREA)
Abstract
The invention is a gastric acid neutralizing antacid agent in liquid form which comprises an aqueous solution of a water-soluble polyethyleneimine, at least one taste improving acid selected from the group consisting of alginic acid, polygalacturonic acid, galacturonic acid, pectin, tannic acid, arabic acid, galactaric acid, and glutaric acid, and at least one acid selected from the group consisting of tartaric acid, fumaric acid, phosphoric acid, acetic acid, citric acid, succinic acid, and malic acid, the latter in such an amount that pH is 4 to 11, and a process for preparing the antacid agent. The antacid agent overcomes various disadvantages of previously known antacid agents containing aluminum hydroxide.
Description
The present invention relates to a gastric acid neutralising agent in the form of a solution, a process for its preparation, and a method for neutralizing gastric acid in mammals.
The present invention provides a gastric acid neutralizing solution which gives a fast reaction with an acid, has a high acid neutralizing capacity, is not absorbed and does not give pharmacologically systemic effects, is well tolerated and is well tasting and has a good consistency.
An antacid ought to have, amongst other things, a high reaction speed with diluted acid and a high acid binding capacity. Hitherto Itnown antacid preparations, which fulful this requirement well contain aluminium hydroxide or related compounds, alone or in coiribination with magnesium salts. Aluminium hydroxide and related compounds have the advantage of reacting relatively fast with acids at a lower pH. The reaction stops, however, when the pH-value rises to about 4. Other compounds having been used to a relatively high extent as an antacid are magnesium silicate and calcium carbonate. Theee two compounds buffer at a somewhat higher pH-value than the aluminium compound and they are partly resorbed. Other magnesium compounds, as the hydroxide and the carbonate, are only used fo a limited extent as such. They are however,
- 2 46208 often combined with aluminium hydroxide, in view of the fact that the compounds themselves give a strong laxative effect, which is neutralized by the combination with aluminium hydroxide. Sodium bicarbonate is a completely water soluble compound which has been used to a certain extent as antacid, as well. This compound, however, raises the pH-value to above the neutral point, which may stimulate an increased secretion of gastric acid. Furthermore it is completely resorbed and may create alkalose.
Most pf the antacid active compounds hitherto used are thus compounds which are difficult to dissolve in water, but which dissolve in gastric juice while reacting with hydrochloric acid. The reaction is not momentaneous, unlike the reaction between an acid and a base in a solution.
In a reaction between a solid and a liquid phase, which is the case here, the reaction speed depends on, amongst other things, the particle size (or more correctly, the contact surface between the phases), the solubility of the solid phase, the crystal structure, possible hydration, It is a well known clinical observation that a liquid preparation of e.g. aluminium hydroxide, gives a better effect than tablets (e.g. Krantz and Carr, Pharmacol, Principles Med. Practic. WilL'iAms and Wilkins, Baltimore 1961, page 391).
One of the float important reasons for this being that the liquid preparations react faster with acid than do the
S' tablets (Sjogren, Farm.Revy. ,t>2, 735, (L9S3).
These hitherto known and used antacids containing a combination of Al- and Mg-salts do, however, show certain drawbacks such as bad taste and chalky consistency, and a relatively slow reactivity with acid. Another drawback using these types of antacids is that an increase in the pH of the urine may occur, which leads to a faster secretion of acidic therapo-’tic agents xvhidi may be administered • * y.
simultaneously. Interaction with other drugs, e.g.
anticholinergic agents and tetracyclines, in the gastrointestinal tract saay occur as well, so that the.latter are reoorbad to a lesser degree than intended.
It has now surprisingly been found possible to overcome the above drawbacks of existing antacids by means of the present invention which provides a gastric acid neutralizing antacid agent in the form of an aqueous solution comprising a water soluble polyethyleneimine, at least one taste-improving acid which is alginic acid, polygalacturonic acid, galacturonic acid, pectin, tannic acid, arabic acid, galactaric acid, or glutaric acid, and at least one pH regulating acid which is tartaric acid, fumaric acid, phosphoric acid, acetic acid, citric acid, succinic -acid, or malic acid, the latter acid being present in such an amount that the pH of the solution is 4 to 11.
It is preferred to use a water soluble polyethylene imine having a molecular weight of 500 to 5000, and which,
- 4 4S303 preferably, has a viscosity of about 200 cps when present in a 50% aqueous solution.
The aqueous solution may be prepared as a concentrate containing up to 60% by weight of polyethylene5 imine which can be diluted before use; the aqueous solution for direct administration should preferably contain 10 to 40% by weight of polyethyleneimine.
The gastric acid neutralizing agent of the invention may be prepared by a process wherein an aqueous solution of the polyethyleneimine is added to the tasteinproving acid and the pH regulating acid is then added to the mixture in an amount such that the pH of the aqueous solution is 4 to 11.
According to a further aspect of the invention, a method for treatment of hyperacidity and ulcer disease in mammals comprises administering orally an agent according to the present invention.
The agent as prepared has the ability of neutralizing the acid of the gastric juice in the stomach to a desired pH without giving anyunsuitable side effects.
The polyethyleneimines used in the present invention, are water soluble polyethyleneimines of the formula •*F·
- 5 H2N-(CH2CH2N-)x-(CH2CH2NH)y-
|Η2
-Νο£ which suitable qualities are sold under the marks G35 and G50 by BASF (Badische Anilin und Soda Fabriken), Federal Republic of Germany, and under the marks PEI 6, PEI 12 and
PEI 18 by Itew chemicals, U.s.A.
The acid used to regulate the pH of the solution is preferably citric acid, acetic acid, succinic acid, or malic acid.
In order to improve palatability, it is preferred 10 to use alginic acid, polygalacturonic acid, galacturonic acid, or pectin as the taste improving acid. The amount of taste improving acid can be 1-10, and is preferably
1-5%. of the weight cf the agent.
In order to get the best palatability, it is 15 preferred to add the polyethyleneimine as an aqueous solution to a solution of the taste improving acid, whereupon the pH-regulating acid is added until the desired pH is reached.
The invention will be described more in detail 20 below with reference to the Examples given.
- 6 48308
EXAMPLE 1 Polyethyleneimine 100% (G35, BASF) 250 Alginic acid 20 Citric acid 100 Water ad looo
The alginic acid was dissolved in 380 mis. of water. Then the polyethyleneimine was added as a 50% aqueous solution. After careful stirring,the pH value was adjusted to 7.3 by adding the citric acid. The resulting solution was a clear, light yellow solution.
EXAMPLE 2
Polyethyleneimine 100% (G35, BASF) 250 g.
Galacturonie acid 20 g.
Acetic acid 160 g.
Wafer ad 1000 g.
The galacturonie acid was dissolved in 320 ml*, of water, whereut.·.·? tne polyethyleneimine was added ae a 50% solution. After careful mixing, the acetic acid was added, whereby a clear, faintly orange solution having a pH of 7.5 was obtained.
EXAMPLE 3
Polyethyleneimine G35, 100% 240 Polygalacturonie acid 16 Phosphoric acid 200 Water ad 1000
53θ8
The preparation is prepared in accordance with
Example 1 above, the final pH vzas 6.0.
EXAMPLE 4
Polyethyleneimine G 35 210 g.
Poiygalaeturonic acid 14 g.
Phosphoric acid 205 g.
Acetic acid 90 g.
Water ad 1000 g.
The preparation was prepared in accordance with 10 Example 1 above, the final pH was 5.0.
EXAMPLE 5
Polyethyleneimine (100%) 250 g.
Pectin 20 g.
Acetic acid 150 g.
Water ad 1000 g.
The preparation is obtained in accordance with
Example 1 above, the final pH was about 7.
EXAMPLE 6
Polyethyleneimine (100%) 230 g.
Arabic acid 13 g.
Phosphoric acid 230 g.
Water ad 1000 g.
The preparation is obtained in accordance with Example 1 above, the final pH was 5.4.
- 8 40303
EXAMPLE 7
Polyethyleneimine (100%)
Tannic acid
Acetic acid
Water
The preparation ia obtained in Example 1 abc*·, the final pH was 7.6.
EXAMPLE 8
Polyethyleneimine
Alginic acid
Succinic acid
Water
The preparation is obtained in Example 1 above, the final pH was 7.1.
EXAMPLE 9
260 g. 17 g.
130 g. ad 1000 g.
accordance with
250 g. 17 g.
170 g. ad 1000 g.
accordance with
Polyethyleneimine (100%) 250 g. Galactaric acid 17 g. Acetic acid 130 g. Water ad 1000 g.
The preparation is prepared in accordance with
Example 1 above, the final pH was about 7.5.
EXAMPLE 10
Polyethyleneimine (100%) 250 Glutaric aeid 17 Acetic acid 130 Water ad 1000
- 9 The preparation is prepared in accordance with
Example 1 above, the final pH was about 7.5.
EXAMPLE 11
Polyethyleneimins (100%) 250 g.
Alginic acid 20 g.
Malic acid 170 g.
Water ad 1000 g„
The preparation is prepared in accordance with Example 1 above, the final pH was about 7.3. Fumaric acid or tartaric acid may be used in place of the malic acid.
EXAMPLE 12
Polyethylaneimine (100%) 250 g.
Polygalacturonic acid 50 g.
Alginic acid 25 g.
Phosphoric acid 100 g.
Water ad 1000 g.
The preparation was prepared by dissolving polygalacturonic acid and alginic acid in 325 mis. of water. Polyethyleneixnine was then added as a 50% aqueous solution. After thorough stirring, the phosphoric acid v/as added. The final pH v/as 7.5.
4K308
EXAMPLE 13 Polyethyleneimi ne (100%) 250 g· Alginic acid 50 g· Arabic acid 25 g« Succinic acid 80 g· Water ad 1000 g. Alginic acid and arabic acid were dissolved in
345 mis. of weoer. Polyethy leneimir,e was then added as a 50% aqueous solution. After thorough stirring, succinic acid was added. The final pH was 7.6.
EXAMPLE 14
Polyethyleneimine (100%) 250 g. Alginic acid ** 30 g. Galactaric acid . 30 g. Phosphoric acid 100 g. 'Water ad 1000 g. The preparation was prepared in accordance with
Examples 12-13 above. The final pH was 7.6.
The acid neutralizing capacities of the preparations above are 40-50 mis. of 0.1N HCl/g. of 25% aqueous solution of polyethyleneimine. The reaction is finished with 1-2 minutes.
Ths daily dose of a preparation according to the invention depends very much on the degree of hyperacidity the patient is suffering. Normal cases, however, require an £SS°8 amount of 8 to 40 g/24 hrs. of the preparation when the preparation contains 25% of the polyethyleneimine.
Single doses are 2-4 g., which are administered 4 to 10 times/24 hrs. The specific weight of the preparations above is about 1.25 g/ml.
Claims (11)
1. A gastric acid neutralizing antacid agent in the form of an aqueous solution comprising a water soluble polyethyleneimine, at least one taste-improving acid which is alginic acid, poiygalaeturonic acid, galacturonic acid, pectin, tannic acid, arabic acid, galactaric acid, or qlutaric acid, and at least one pH regulating acid which is tartaric ac.id, fumaric acid, phosphoric acid, acetic acid, citric acid, succinic acid, or malic acid, the latter acid being present in such an amount that the pH of the solution is 4 tc il.
2. An agent according to claim X wherein the polyethyleneimine is one having a molecular weight of 500 to 5000.
3. An rrtnt according to claim 1 or 2, wherein the polyethyleneimine is one that,in a 50% aqueous solution, gives a viscosity of about 200 cps.
4. An agent according to any one of the preceding claims in the form of a concentrate having a concentration of polyethyleneimine up to 60% by weignt and which can be diluted prior to administration.
5. An agent according to any one of claims 1-3 in the form of a solution ready for administration and having a concentration of polyethyleneimine of 10 to 40% by weight. - 13 e S 2 θ θ
6. An agent according to any one of the preceding claims, wherein the taste-improving acid is present in an amount of 1 to W by weight.
7. An agent according to claim 6 wherein the tasteimproving acid is present in an amount of 1-5½ by weight.
8. An agent according to claim 1 substantially as hereinbefore described with refererence to any one of the Examples.
9. A process for preparing an agent according to any one of the preceding claims wherein an aqueous solution of the polyethyleneimine is added to the taste-improving acid and the pH regulating acid is then added to the mixture in an amount such that the pH of the aqueous solution is 4 to 11.
10. A process according to claim 9 substantially as hereinbefore described with reference to any one of the Examples.
11. An agent obtained by a process according to claim 9 or 10.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE7606256A SE405445B (en) | 1976-06-03 | 1976-06-03 | PROCEDURE FOR THE PREPARATION OF A STOMACH ACID NEUTRALIZING ANTACIDUM IN LIQUID CONTAINING POLYETHYLENIMINE |
Publications (2)
Publication Number | Publication Date |
---|---|
IE45208L IE45208L (en) | 1977-12-03 |
IE45208B1 true IE45208B1 (en) | 1982-07-14 |
Family
ID=20328121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE1120/77A IE45208B1 (en) | 1976-06-03 | 1977-05-31 | Neutralizing agent |
Country Status (21)
Country | Link |
---|---|
JP (1) | JPS52148630A (en) |
AT (1) | AT353406B (en) |
AU (1) | AU514929B2 (en) |
BE (1) | BE855349A (en) |
CA (1) | CA1087094A (en) |
CS (1) | CS207459B2 (en) |
DD (1) | DD131345A5 (en) |
DE (1) | DE2722486A1 (en) |
DK (1) | DK234077A (en) |
FI (1) | FI59023C (en) |
FR (1) | FR2353296A1 (en) |
GB (1) | GB1539162A (en) |
HU (1) | HU174584B (en) |
IE (1) | IE45208B1 (en) |
LU (1) | LU77480A1 (en) |
NL (1) | NL7706085A (en) |
NO (1) | NO771899L (en) |
NZ (1) | NZ184237A (en) |
SE (1) | SE405445B (en) |
SU (1) | SU812156A3 (en) |
ZA (1) | ZA772913B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5936192B2 (en) * | 2012-10-25 | 2016-06-15 | 学校法人神奈川大学 | Chiral supramolecular crystal, solid catalyst comprising the same, and method for producing chiral supramolecular crystal |
-
1976
- 1976-06-03 SE SE7606256A patent/SE405445B/en unknown
-
1977
- 1977-05-16 ZA ZA00772913A patent/ZA772913B/en unknown
- 1977-05-18 DE DE19772722486 patent/DE2722486A1/en not_active Withdrawn
- 1977-05-24 FI FI771660A patent/FI59023C/en not_active IP Right Cessation
- 1977-05-27 DK DK234077A patent/DK234077A/en unknown
- 1977-05-30 NZ NZ184237A patent/NZ184237A/en unknown
- 1977-05-30 AU AU25612/77A patent/AU514929B2/en not_active Expired
- 1977-05-31 IE IE1120/77A patent/IE45208B1/en unknown
- 1977-05-31 NO NO771899A patent/NO771899L/en unknown
- 1977-06-01 HU HU77HE737A patent/HU174584B/en unknown
- 1977-06-01 CS CS773612A patent/CS207459B2/en unknown
- 1977-06-01 DD DD7700199241A patent/DD131345A5/en unknown
- 1977-06-02 FR FR7716916A patent/FR2353296A1/en active Granted
- 1977-06-02 SU SU772490602A patent/SU812156A3/en active
- 1977-06-02 GB GB23486/77A patent/GB1539162A/en not_active Expired
- 1977-06-02 CA CA279,734A patent/CA1087094A/en not_active Expired
- 1977-06-02 NL NL7706085A patent/NL7706085A/en not_active Application Discontinuation
- 1977-06-03 LU LU77480A patent/LU77480A1/xx unknown
- 1977-06-03 BE BE178155A patent/BE855349A/en unknown
- 1977-06-03 AT AT393877A patent/AT353406B/en not_active IP Right Cessation
- 1977-06-03 JP JP6568177A patent/JPS52148630A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
FI771660A (en) | 1977-12-04 |
FI59023C (en) | 1981-06-10 |
DE2722486A1 (en) | 1977-12-22 |
HU174584B (en) | 1980-02-28 |
NO771899L (en) | 1977-12-06 |
BE855349A (en) | 1977-12-05 |
FR2353296A1 (en) | 1977-12-30 |
ATA393877A (en) | 1979-04-15 |
AU2561277A (en) | 1978-12-07 |
AU514929B2 (en) | 1981-03-05 |
CA1087094A (en) | 1980-10-07 |
SU812156A3 (en) | 1981-03-07 |
CS207459B2 (en) | 1981-07-31 |
ZA772913B (en) | 1978-04-26 |
NL7706085A (en) | 1977-12-06 |
JPS52148630A (en) | 1977-12-10 |
DD131345A5 (en) | 1978-06-21 |
FI59023B (en) | 1981-02-27 |
FR2353296B1 (en) | 1981-01-16 |
GB1539162A (en) | 1979-01-31 |
IE45208L (en) | 1977-12-03 |
AT353406B (en) | 1979-11-12 |
NZ184237A (en) | 1979-10-25 |
LU77480A1 (en) | 1978-01-26 |
DK234077A (en) | 1977-12-04 |
SE7606256L (en) | 1977-12-04 |
SE405445B (en) | 1978-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1254143A (en) | Pharmaceutical preparation with a content of ibuprofen, and process for its preparation | |
US7094429B2 (en) | Process for preparing tannate liquid and semi-solid dosage forms | |
CA1305057C (en) | Calcium salts | |
JPS61246120A (en) | Floating long life releasable therapeutical composition | |
US20040013695A1 (en) | Oral solid dose vaccine | |
AU2001286168A1 (en) | Oral solid dose vaccine | |
US4704278A (en) | Fluidized magaldrate suspension | |
US3794722A (en) | Iron composition for treating anemia | |
JP2024525095A (en) | Alginates, polylysine, and seed preservatives Nutritional products and digestive aids | |
IE45208B1 (en) | Neutralizing agent | |
US4191744A (en) | Neutralizing agent | |
US4465667A (en) | Process for the preparation of gastric acid neutralizing agents, gastric acid neutralizing agents, and a method for treating hyperacidity and disorders related thereto | |
EP0725630A1 (en) | Fast dissolving dosage forms containing magnesium aluminum silicate and multiple active ingredients | |
US3347744A (en) | Magnesium hydroxide suspensions | |
US2294889A (en) | Medicinal product | |
EP0715520B1 (en) | Use of a suspension based on sucralphate gel as antacid | |
WO2006100527A1 (en) | Effervescent tablet containing sodium alendronate and related use and process | |
AU2012286514B2 (en) | Oral compositions comprising an antacid, an anaesthetic and an inorganic matrix comprising silicon dioxide and titanium dioxide | |
JPH0655677B2 (en) | Fluidized magaldrate composition | |
US20170136061A1 (en) | Supplemented antacid formulation | |
CA1252045A (en) | Fluidized magaldrate suspension | |
KR102303835B1 (en) | Aqueous flowable liquid composition and preparing methode thereof | |
AU604721B2 (en) | Proceeding for the production of pharmaceutical preparations of high gastric acid binding capacity, of retarded effect and of increased bioavailability | |
JPS6322017A (en) | Medicinal composition containing indomethacin and manufacture | |
CN118236324A (en) | Sulfosamine oral preparation and preparation method thereof |